Related Experiment Video

Updated: May 9, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The pharmacology of novel oral anticoagulants

Tracy A DeWald1, Richard C Becker

  • 1Divisions of Clinical Pharmacology (TAD) and Cardiovascular Medicine (RCB) Duke University Medical Center, Duke Clinical Research Institute (RCB), Durham, NC, USA, dewal001@mc.duke.edu.

Journal of Thrombosis and Thrombolysis
|July 18, 2013
PubMed

Insights

Novel anticoagulants like rivaroxaban, apixaban, and dabigatran are effective for stroke prevention in atrial fibrillation. Understanding their unique pharmacokinetic profiles is key to safe and effective patient selection and treatment.

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiology

Background:

  • Atrial fibrillation management requires effective stroke prevention.
  • Novel oral anticoagulants (NOACs) offer alternatives to traditional therapies.
  • Non-valvular atrial fibrillation (NVAF) is a common indication for anticoagulation.

Purpose of the Study:

  • To review the pharmacokinetics of novel anticoagulants.
  • To summarize the pharmacology of rivaroxaban, apixaban, and dabigatran.
  • To explore reasons for differing bleeding outcomes in clinical trials.

Main Methods:

  • Literature review of pharmacokinetic processes for oral medications.
  • Summary of pharmacology and individual pharmacokinetic features of NOACs.
  • Analysis of clinical trial data regarding bleeding events.

Main Results:

  • NOACs, including factor Xa inhibitors (rivaroxaban, apixaban) and direct thrombin inhibitors (dabigatran), provide stroke prevention in NVAF.
  • These agents have practical advantages over vitamin K antagonists.
  • Individual pharmacokinetic differences may influence efficacy and safety profiles.

Conclusions:

  • Understanding NOAC pharmacokinetics is crucial for optimal patient management.
  • Agent-specific differences necessitate careful consideration for therapy selection.
  • Further exploration of pharmacokinetic and agent-specific factors may explain bleeding outcome variations.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...